3%高渗盐水鼻腔盥洗治疗血管运动性鼻炎的初步研究
101例血管运动性鼻炎患者随机分为对照组、布地奈德组、鼻腔盥洗组和联合治疗组,干预期3个月。布地奈德组和联合治疗组在第1、2个月末VAS降低、SF-12v2升高,鼻腔盥洗组和联合治疗组在第3个月末VAS降低、SF-12v2升高。结论:单纯3%高渗盐水盥洗或联合鼻用糖皮质激素疗效优于单纯鼻用糖皮质激素。
要点
- 联合治疗组第3个月末VAS由6.18±0.17降至4.44±0.13,SF-12v2由146.00±1.08升至152.90±0.85。
- 鼻腔盥洗组第3个月末VAS由5.96±0.17降至4.80±0.12,SF-12v2由146.10±1.17升至150.80±0.96。
- 布地奈德组第3个月末VAS和SF-12v2较治疗前无显著差异(P>0.05)。
核心结论
- 单纯3%高渗温盐水鼻腔盥洗或鼻用糖皮质激素联合鼻腔盥洗长期治疗VMR,其疗效优于单纯鼻用糖皮质激素治疗。
- 糖皮质激素对鼻黏膜感觉神经纤维有一定抑制作用,但神经递质在VMR发病机制中作用有限。
研究设计与样本
- 101例VMR患者随机分为4组:对照组24例、布地奈德组25例、鼻腔盥洗组25例、联合治疗组27例,干预期3个月(90天)。
- 对照组不予任何治疗;布地奈德组用布地奈德鼻腔喷雾;鼻腔盥洗组以3.0%温盐水(40℃)鼻腔盥洗;联合治疗组应用上述两种方法。
- 用VAS评估鼻部症状,SF-12v2评估生活质量;用ELISA检测布地奈德组和鼻腔盥洗组干预前及3个月后鼻腔盥洗液中SP和MUC5B,并检测对照组SP激惹和抗胆碱能药物阻滞后MUC5B浓度。
主要发现
- 第1个月末,布地奈德组VAS由5.91±0.21降至3.82±0.15、SF-12v2由146.00±1.23升至152.30±0.97(P<0.05);联合治疗组VAS由6.18±0.17降至3.92±0.15、SF-12v2由146.00±1.08升至155.40±0.90(P<0.05);鼻腔盥洗组VAS(5.96±0.17 vs 5.72±0.15)和SF-12v2(146.10±1.17 vs 147.00±0.94)无显著差异(P>0.05)。
- 第2个月末,布地奈德组VAS由5.91±0.21降至5.05±0.15、SF-12v2由146.00±1.23升至150.90±0.76(P<0.05);联合治疗组VAS由6.18±0.17降至5.10±0.12、SF-12v2由146.00±1.08升至153.60±0.94(P<0.05);鼻腔盥洗组VAS(5.96±0.17 vs 5.78±0.17)和SF-12v2(146.10±1.17 vs 148.10±0.80)无显著差异(P>0.05)。
- 第3个月末,鼻腔盥洗组VAS由5.96±0.17降至4.80±0.12、SF-12v2由146.10±1.17升至150.80±0.96(P<0.05);联合治疗组VAS由6.18±0.17降至4.44±0.13、SF-12v2由146.00±1.08升至152.90±0.85(P<0.05);布地奈德组VAS(5.91±0.21 vs 5.68±0.18)和SF-12v2(146.00±1.23 vs 148.40±0.85)无显著差异(P>0.05)。
- 布地奈德组干预3个月后鼻腔盥洗液中SP减少、MUC5B无明显变化;鼻腔盥洗组SP无变化、MUC5B显著减少;抗胆碱能药物未能使SP激惹后鼻腔盥洗液中MUC5B含量显著降低。
临床怎么用
- 对VMR患者,可考虑单纯3.0%高渗温盐水(40℃)鼻腔盥洗或与鼻用糖皮质激素联合长期治疗,其疗效优于单纯鼻用糖皮质激素。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To observe the therapeutic effect of simple 3.0% saline nasal irrigation and combined treatment of 3.0% saline nasal irrigation and budesonide nasal spray for vasomotor rhinitis (VMR), and explore the long-term effect for VMR. Through examination of levels of substance P (SP) and mucin (MUC)5B in nasal lavage fluid, the mechanisms of nasal irrigation treatment for VMR was discussed. Methods: One hundred and one patients from Department of Otorhinolaryngology Head and Neck Surgery, Huashan Hospital of Fudan University with VMR were randomly divided into 4 groups. The number of patients was 24 in control group, 25 in budesonide nasal spray treatment group (budesonide group), 25 in nasal irrigation treatment group (nasal irrigation group) and 27 in budesonide nasal spray + nasal irrigation group (combined treatment group). Control patients were left untreated. Budesonide group was under budesonide nasal spray treatment, nasal irrigation group was treated using 3.0% saline with a temperature of 40℃ and combined treatment group was given both treatments. The duration of the intervention period was 3 months (90 days). Visual Analog Scale (VAS) was used to evaluate nasal symptoms, and the health-related quality of life was assessed using the 12-item Short Form Health Survey version 2.0 (SF-12v2). Enzyme-linked immunosorbent assay (ELISA) was used to assess the contents of SP and MUC5B in nasal lavage fluid before and after 3-month treatments in budesonide and nasal irrigation group in the study. MUC5B in nasal lavage fluid after the SP challenge and anticholinergic drug intervention in control group were also evaluated with ELISA. Results: Nighty out of 101 patients completed the study. In the budesonide and combined treatment group after relevant interventions, the total VAS score of nasal symptoms decreased (5.91±0.21 vs 3.82±0.15, 6.18±0.17 vs 3.92±0.15, t value was 8.193, 10.060, respectively, all P<0.05) and SF-12v2 score increased (146.00±1.23 vs 152.30±0.97, 146.00±1.08 vs 155.40±0.90, t value was 3.982, 6.697, respectively, all P<0.05), with both scores showed no significant differences in the nasal irrigation group (5.96±0.17 vs 5.72±0.15, 146.10±1.17 vs 147.00±0.94, t value was 1.038, 0.607, respectively, all P>0.05) after the first month. In the budesonide and combined treatment group after relevant interventions, the total VAS score of nasal symptoms decreased (5.91±0.21 vs 5.05±0.15, 6.18±0.17 vs 5.10±0.12, t value was 3.374, 5.351, respectively, all P<0.05) and SF-12v2 score increased (146.00±1.23 vs 150.90±0.76, 146.00±1.08 vs 153.60±0.94, t value was 3.373, 5.343, respectively, all P<0.05), with both scores showed no significant differences in the nasal irrigation group (5.96±0.17 vs 5.78±0.17, 146.10±1.17 vs 148.10±0.80, t value was 0.716, 1.438, respectively, all P>0.05) after the second month. By the end of the third month, in nasal irrigation and combined treatment group, the VAS score was diminished (5.96±0.17 vs 4.80±0.12, 6.18±0.17 vs 4.44±0.13, t value was 5.485, 8.264, respectively, all P<0.05) and SF-12v2 score was elevated (146.10±1.17 vs 150.80±0.96, 146.00±1.08 vs 152.90±0.85, t value was 3.163, 5.008, respectively, all P<0.05), but there were no significant differences in budesonide group (5.91±0.21 vs 5.68±0.18, 146.00±1.23 vs 148.40±0.85, t value was 0.819, 1.587, respectively, all P>0.05). Additionally, SP in nasal lavage fluid decreased and MUC5B showed no statistical changes in budesonide group after three months, however, SP showed no any changes and MUC5B reduced significantly in nasal lavage fluid in nasal irrigation group. Furthermore, the anticholinergic drug could not decrease the concentration of MUC5B after the SP challenge in nasal cavity in control group. Conclusions: The therapeutic effect of simple nasal irrigation with 3.0% saline or combined treatment of 3.0% saline nasal irrigation and nasal corticosteroids is superior to simple nasal corticosteroids. Nasal corticosteroids plays a role in the inhibition of sensory nerve endings in nasal mucosa, but neurotransmitter plays a limited role in the pathogenesis of VMR. 目的: 观察单纯3%高渗盐水鼻腔盥洗及与鼻用糖皮质激素联合的方法对血管运动性鼻炎(vasomotor rhinitis,VMR)的治疗作用;通过检测鼻腔盥洗液中P物质(substance P,SP)和黏蛋白(mucin,MUC)5B的含量,初步探讨鼻腔盥洗治疗VMR的机制。 方法: 就诊于复旦大学附属华山医院耳鼻咽喉头颈外科的101例VMR患者被随机分为4组:对照组24例,布地奈德鼻腔喷雾治疗组(布地奈德组)25例,鼻腔盥洗治疗组(鼻腔盥洗组)25例,布地奈德鼻腔喷雾+鼻腔盥洗治疗组(联合治疗组)27例。对照组患者不予任何治疗措施,布地奈德组用布地奈德进行鼻腔喷雾,鼻腔盥洗组以3%的温盐水(40℃)进行鼻腔盥洗,联合治疗组应用上述两种治疗方法,干预期为3个月(90 d)。用视觉模拟量表(visual analog scale,VAS)评估患者鼻部症状,用健康调查量表(12-item short form health survey version 2.0,SF-12v2)评估患者生活质量。用酶联免疫吸附试验(ELISA)对布地奈德组和鼻腔盥洗组患者干预前和干预后3个月时的鼻腔盥洗液中SP和MUC 5B进行检测,并检测对照组鼻腔SP激惹和抗胆碱能药物阻滞后鼻腔盥洗液中的MUC5B浓度。应用Graphpad Prism 6统计软件进行统计学分析。 结果: 101例VMR患者中90例完成了该项研究。干预后第1个月末,布地奈德组和联合治疗组治疗前后的VAS评分降低[(5.91±0.21)分比(3.82±0.15)分,(6.18±0.17)分比(3.92±0.15)分,t值分别为8.193、10.060,P值均<0.05],SF-12v2评分升高[(146.00±1.23)分比(152.30±0.97)分,(146.00±1.08)分比(155.40±0.90)分,t值分别为3.982、6.697,P值均<0.05],但鼻腔盥洗组的VAS评分[(5.96±0.17)分比(5.72±0.15)分,t=1.038,P>0.05]和SF-12v2评分[(146.10±1.17)分比(147.00±0.94)分,t=0.607,P>0.05]的差异无统计学意义。第2个月末,布地奈德组和联合治疗组治疗前后的VAS评分降低[(5.91±0.21)分比(5.05±0.15)分,(6.18±0.17)分比(5.10±0.12)分,t值分别为3.374、5.351,P值均<0.05],SF-12v2评分升高[(146.00±1.23)分比(150.90±0.76)分,(146.00±1.08)分比(153.60±0.94)分,t值分别为3.373、5.343,P值均<0.05],但鼻腔盥洗组的VAS评分[(5.96±0.17)分比(5.78±0.17)分,t=0.716,P>0.05]和SF-12v2评分[(146.10±1.17)分比(148.10±0.80)分,t=1.438,P>0.05]的差异无统计学意义。第3个月末,鼻腔盥洗组和联合治疗组治疗前后的VAS评分降低[(5.96±0.17)分比(4.80±0.12)分,(6.18±0.17)分比(4.44±0.13)分,t值分别为5.485、8.264,P值均<0.05],SF-12v2评分升高[(146.10±1.17)分比(150.80±0.96)分,(146.00±1.08)分比(152.90±0.85)分,t值分别为3.163、5.008,P值均<0.05],但布地奈德组的VAS评分[(5.91±0.21)分比(5.68±0.18)分,t=0.819,P>0.05]和SF-12v2评分[(146.00±1.23)分比(148.40±0.85)分,t=1.587,P>0.05]的差异无统计学意义。布地奈德组干预3个月后鼻腔盥洗液中SP减少,MUC5B未出现明显变化,而鼻腔盥洗组的结果正好相反,并且,抗胆碱能药物未能使SP激惹后的鼻腔盥洗液中MUC5B的含量显著降低。 结论: 单纯3%高渗温盐水鼻腔盥洗或鼻用糖皮质激素联合鼻腔盥洗长期治疗VMR,其疗效优于单纯鼻用糖皮质激素治疗。糖皮质激素对鼻黏膜感觉神经纤维有一定的抑制作用,但神经递质在VMR的发病机制中作用有限。.
引用
- Lin L, Lu Q, Tang XY, et al. [Nasal irrigation for the treatment of vasomotor rhinitis: a pilot study]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017. PMID: 28635218. doi:10.3760/cma.j.issn.1673-0860.2017.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。